The 36-month beta value for NRXP is at 1.46. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NRXP is 14.28M, and currently, shorts hold a 8.49% of that float. The average trading volume for NRXP on May 13, 2025 was 169.95K shares.
NRXP) stock’s latest price update
The stock of NRX Pharmaceuticals Inc (NASDAQ: NRXP) has increased by 2.40 when compared to last closing price of 2.08.Despite this, the company has seen a gain of 10.94% in its stock price over the last five trading days. prnewswire.com reported 2025-05-13 that Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide Kadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this space Dr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE MIAMI, May 13, 2025 /PRNewswire/ — HOPE Therapeutics™, Inc. (“HOPE”), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy.
NRXP’s Market Performance
NRXP’s stock has risen by 10.94% in the past week, with a monthly rise of 3.90% and a quarterly drop of -27.80%. The volatility ratio for the week is 5.87% while the volatility levels for the last 30 days are 6.02% for NRX Pharmaceuticals Inc The simple moving average for the last 20 days is 5.55% for NRXP’s stock, with a simple moving average of 6.60% for the last 200 days.
Analysts’ Opinion of NRXP
Many brokerage firms have already submitted their reports for NRXP stocks, with BTIG Research repeating the rating for NRXP by listing it as a “Buy.” The predicted price for NRXP in the upcoming period, according to BTIG Research is $18 based on the research report published on April 02, 2025 of the current year 2025.
NRXP Trading at 5.08% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.56% of loss for the given period.
Volatility was left at 6.02%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares surge +5.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.91% upper at present.
During the last 5 trading sessions, NRXP rose by +11.98%, which changed the moving average for the period of 200-days by -8.12% in comparison to the 20-day moving average, which settled at $2.02. In addition, NRX Pharmaceuticals Inc saw -3.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRXP starting from Javitt Jonathan C, who purchase 40,000 shares at the price of $1.17 back on Dec 17 ’24. After this action, Javitt Jonathan C now owns 84,634 shares of NRX Pharmaceuticals Inc, valued at $46,800 using the latest closing price.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -4625.5 for the present operating margin
The net margin for NRX Pharmaceuticals Inc stands at -6281.5. The total capital return value is set at 1.02.
Based on NRX Pharmaceuticals Inc (NRXP), the company’s capital structure generated -0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -1.71. The debt to equity ratio resting at -0.28. The interest coverage ratio of the stock is -80.44.
Currently, EBITDA for the company is -18.5 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 10541.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.15.
Conclusion
In conclusion, NRX Pharmaceuticals Inc (NRXP) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
